New anticancer drugs targeting EGFR signaling have been developed to treat different types of cancer, including the EGFR tyrosine kinase inhibitors (TKIs), which directly inhibit EGFR tyrosine kinase activity and are currently being used for treating locally advanced or metastatic NSCLC [12–14]. Here, EGFR is linked to non-small cell lung carcinoma.